


**SCHOOL OF
MEDICINE IN NEW ORLEANS**

Louisiana State University
Medical Center
2020 Gravier Street, Suite "B"
New Orleans, LA 70112-2234
Telephone: (504) 568-6700
Telefax: (504) 568-5801



Neuroscience Center
Office of the Director

27 May, 1993

Dr. Marshall Nirenberg
Laboratory of Biochemical Genetics
NIH-National Heart Lung Institute
Building 36, Room 1C06
Bethesda, MD 20892

Dear Marshall:

I would like to bring you up-to-date on the neuroscience company established by Lloyd Horrocks and myself originally called **BrainChemTech**. Recently, we have decided to rename it as **B&H Pharmaceuticals, Inc.** It was very kind of you to agree to be a scientific advisor to this company when I contacted you a few months ago. I would like to reaffirm this relationship with you. As I mentioned at that time, Lloyd will be full time in the company and I will Chair the Scientific Advisory Board. I plan to continue to devote most of my time to my current university research laboratory.

The company has recently picked up momentum and seems ready to be launched. We have enlisted the services of Dr. Alex To in putting the start-up activities together. Dr. To is a very experienced management consultant and was previously vice president of a large New York venture capital firm which specialized in medical product companies. We have interviewed a series of CEO candidates as Chief Executive Officer and will make the final selection shortly. The company is also under negotiation with several institutions in order to obtain licenses to patents.

Most importantly, we are under discussion with venture capital firms and investors, and it looks very likely that the funding will be in place in the near future. Some of these investors may contact you in their due diligence process. I am wondering if you would be so kind as to take time from your busy schedule and answer their inquiries, please give your honest opinion to any question the investors may have.

To reiterate my previous communication, the main theme to of the company is to apply signal transduction technology to develop drugs to treat neurological diseases. Products include neuroprotective agents, CDP-ethanolamine, and a slow release dopamine microcapsule, among others.

Thanks again for your kind support. I hope that I will be in the position to discuss specific terms of your advisorship in the near future.

Best regards,

A handwritten signature in black ink, appearing to read 'Nicolas', with a long, sweeping horizontal stroke extending to the left.

Nicolas G. Bazan, M.D., Ph.D.
Professor of Ophthalmology,
Biochemistry and Molecular Biology,
and Neurology
Director, Neuroscience Center

NGB/zfd